Proglucagon-derived peptides: mechanisms of action and therapeutic potential.

Abstract

Glucagon is used for the treatment of hypoglycemia, and glucagon receptor antagonists are under development for the treatment of type 2 diabetes. Moreover, glucagon-like peptide (GLP)-1 and GLP-2 receptor agonists appear to be promising therapies for the treatment of type 2 diabetes and intestinal disorders, respectively. This review discusses the physiological, pharmacological, and therapeutic actions of the proglucagon-derived peptides, with an emphasis on clinical relevance of the peptides for the treatment of human disease.

• Authors: Elaine M Sinclair, Daniel J Drucker
• Journal: Physiology (Bethesda, Md.) (Physiology (Bethesda)) Vol. 20 Pg. 357-65 (Oct 2005) ISSN: 1548-9213 [Print] United States
• PMID: 16174875 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• GLP1R protein, human
• Glucagon-Like Peptide 2
• Glucagon-Like Peptide-1 Receptor
• Peptide Fragments
• Peptides
• Protease Inhibitors
• Protein Precursors
• Receptors, Glucagon
• Proglucagon
• Glucagon-Like Peptides
• Glucagon-Like Peptide 1
• Glucagon
• Dipeptidyl Peptidase 4

Topics

• Animals
• Diabetes Mellitus, Type 2 (drug therapy)
• Dipeptidyl Peptidase 4 (drug effects)
• Disease
• Glucagon (analogs & derivatives, physiology, therapeutic use)
• Glucagon-Like Peptide 1
• Glucagon-Like Peptide 2
• Glucagon-Like Peptide-1 Receptor
• Glucagon-Like Peptides (physiology)
• Humans
• Intestinal Diseases (drug therapy)
• Peptide Fragments (physiology, therapeutic use)
• Peptides (metabolism, physiology, therapeutic use)
• Proglucagon
• Protease Inhibitors (therapeutic use)
• Protein Precursors (physiology, therapeutic use)
• Receptors, Glucagon (agonists, physiology)